Side by side: size, value over time, results, valuation, margins, growth, debt and shareholder returns, and any of thirty figures charted over the years (up to 6).
Open these as a peer group: up to 12 companies with suggested peers, each company's rank in the group and percentile in its sector and country, saved for you or your team.
From Dec 2022: how each company's value moved, whatever its size.
US$ billions, as reported in each year's annual results.
Revenue of the fiscal year. US dollars at each year's exchange rate.
| Measure | AbbVie Inc.✕ ABBV · #26 in the world | Renascience Inc.✕ 4889.T |
|---|---|---|
| Profile | ||
| Country | 🇺🇸 USA | 🇯🇵 Japan |
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceutical | — |
| Founded | 2013 | — |
| Size | ||
| Market cap | ||
The largest companies, each against its nearest peers in value from the same industry.
| Fiscal year | AbbVie Inc. | Renascience Inc. |
|---|---|---|
| 2025 | $61.2 BSEC | — |
| 2024 | $56.3 BSEC | — |
| 2023 | $54.3 BSEC | — |
| 2022 | $58.1 BSEC | — |
| 2021 | $56.2 BSEC | — |
| 2020 | $45.8 BSEC | — |
| 2019 | $33.3 BSEC | — |
| 2018 | $32.8 BSEC | — |
| 2017 | $28.2 BSEC | — |
| 2016 | $25.6 BSEC | — |
| 2015 | $22.9 BSEC | — |
| 2014 | $20.0 BSEC | — |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports; Ed. = the company's report (editors); WD = Wikidata, citing the annual report; Cap = value.today market caps. Hover a figure for its period.
| $514.0 B |
| $163 M* |
| Revenue | $61.2 B | — |
|---|
| Net income | $4.2 B | — |
|---|
| Employees | 57,000 | — |
|---|
| Valuation | ||
|---|---|---|
| P/E ratio | 49.7× | — |
| Price to sales | 7.8× | — |
| Free cash flow yield | 3.5% | — |
| Profitability | ||
|---|---|---|
| Gross margin | 70.2% | — |
| Operating margin | 24.6% | — |
| Net margin | 6.9% | — |
| Return on invested capital | 16.0% | — |
| Growth | ||
|---|---|---|
| Revenue growth | 8.6% | — |
| Revenue growth, 3 years a year | 1.8% | — |
| Earnings per share growth | -1.3% | — |
| Financial strength | ||
|---|---|---|
| Interest cover | 5.2× | — |
| Cash | ||
|---|---|---|
| Free cash flow margin | 29.1% | — |
| Shareholder returns | ||
|---|---|---|
| Dividend yield | 2.3% | — |
| Shareholder yield | 2.5% | — |
| Strength scores | ||
|---|---|---|
| Piotroski F-score | 8 of 9 | — |
| Altman Z-score zone | grey | — |
|---|
| Data as of | Market cap Oct 2026; ratios FY2025 | Market cap Mar 2026 |
|---|
Market caps from exchange data or SEC filings on the date shown (* last known value, no current one); revenue and net income from the latest annual results; ratios worked out from each company's own statements for the fiscal year shown. ▲ marks the best of these companies where higher or lower is better; size and valuation multiples are marked for no one. Definitions: methodology.